Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study
This study presents the first analysis of safety and efficacy of DRF in Black patients. Relapse rates remained low in Black patients on DRF, consistent with non-Black patients, and there were no new safety signals identified in the Black patient subgroup in EVOLVE-MS-1. Together, these outcomes support DRF as an effective treatment option in Black patients with RRMS.
Authors
- Zhe Tian (ORCID: https://orcid.org/0000-0002-9482-6473)
- Samuel F. Hunter (ORCID: https://orcid.org/0000-0002-0542-1176)
- Seth Levin (ORCID: https://orcid.org/0000-0001-9222-1094)
- Matthew Scaramozza (ORCID: https://orcid.org/0000-0003-3738-459X)
- John Lindsey (ORCID: https://orcid.org/0000-0001-6856-0811)
- Ariel Antezana
- Benjamin Osborne
- James B. Lewin (ORCID: https://orcid.org/0000-0002-2352-9113)
- Filipe Branco
- Bethany Schreiber
Institutions
- Biogen (United States) (US)
- Georgetown University (US)
- MedStar Georgetown University Hospital (US)
- NeuroMedical Center (US)
- Biogen (Switzerland) (CH)
- NeuroNexus (United States) (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.msard.2024.105912
- Citations
- 3
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- Biogen